Skip to content

MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos Therapy: Feasibility Study

MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05909111
Acronym
Ethos Col
Enrollment
15
Registered
2023-06-18
Start date
2022-12-01
Completion date
2026-02-01
Last updated
2025-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, MRI, Online Adaptative Radiation Therapy

Brief summary

Current management of patients treated with External Beam Radiation Therapy (EBRT) for cervical cancer with a classical Image-guided Radiation Therapy (IGRT) strategy involves a complex, not entirely satisfactory, treatment workflow. Indeed, in our institution, two workflows have been designed to take into account the inter-fraction motion of cervix and uterus : an Internal Target Volume (ITV)-based approach and a plan of the day strategy requiring both several planning-CT (Computed Tomography) acquisitions with variable bladder filling.The upcoming installation of a Varian Ethos therapy system in our institution will allow us to implement a less cumbersome online adaptive radiotherapy strategy (oART), which, by conforming to the daily anatomy, will enable a reduction in the Clinical Target Volume (CTV) to Planning Target Volume (PTV) margins leading to an expected reduction in dose delivered to organs at risk (OAR) .On the other hand, MR (Magnetic Resonance)-only treatment planning is playing an increasing role in radiotherapy, notably in the treatment of prostate cancer. MR-only workflows are known (a) to provide the most reliable delineation in soft tissues and (b) to decrease spatial uncertainties by suppressing the Magnetic Resonance Imaging (MRI)-CT co-registration. Regarding the management of cervical cancer, the importance of MRI is well established and its use becomes essential. Combining a MR-only workflow with an adaptative one on the Varian Ethos system, could lead to an improved management of patients treated for cervical cancer with an expected reduction in margins and volumes treated (thanks to MRI delineation and online adaptation) and therefore a reduction of OAR toxicity. Including regular multi-parametric MR imaging during and after the course of the treatment could also provide in the future an assessment of the treatment response. One of the important challenges in developing this specific workflow is to have a reliable synthetic CT (derived from MRI) to (a) provide electron or mass density for treatment planning calculations and (b) allow accurate online repositioning/deformation with Ethos Cone Beam Computed Tomography (CBCT). The other fundamental challenge is to provide a formal assessment of the clinical benefit of introducing MR-only simulation and planning in an oART workflow. This project aims to demonstrate the feasibility of setting up an adaptive workflow on the ETHOS platform with the sole use of MR patient image.The project is divided into two parts. The first part consists in demonstrate the feasibility of the workflow on 15 patients with cervix cancer.

Interventions

DIAGNOSTIC_TESTMagnetic resonance imaging

MRI weekly during the radiation treatment course (5 RMI added to the standard care)

Sponsors

Varian Medical Systems
CollaboratorINDUSTRY
Recherche clinique
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years old * Histologically proven cervical cancer (SCC, ADK ou adenous-SCC) * Patient for curative RTCT treatment * FIGO/TNM Stage IB2, IIA, IIB, IIIA, IIIB with or without lymph nodes involvement * WHO \< 2 * No pregnancy * Informed consent dated and signed * Patient affiliated or beneficiary of a social security scheme * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion criteria

* Metastatic disease * Contraindications to IRM examinations (claustrophobia, presence of metallic elements..) * Signes of active infection or serious health problems * Historic of abdominal or pelvis RT * Surgical history: partial or total hysterectomy

Design outcomes

Primary

MeasureTime frameDescription
Tumor regression assessment CBCT18 monthsVolume Tumor regression on CBCT
Tumor regression assessment MRI18 monthsVolume Tumor regression on MRI

Countries

France

Contacts

Primary ContactCatherine Khamphan, PhD
c.khamphan@isc84.org0490276543
Backup ContactAurélien Badey
a.badey@isc84.org0490276563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026